Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19

被引：76
|
作者：
Praveen, D. [1 ]
Puvvada, Ranadheer Chowdary [1 ]
Aanandhi, Vijey M. [2 ]
机构：
[1] Vels Inst Sci Technol & Adv Studies, Sch Pharmaceut Sci, Chennai 600117, Tamil Nadu, India
[2] Vels Inst Sci Technol & Adv Studies, Sch Pharmaceut Sci, Dept Pharmaceut Chem & Anal, Chennai, Tamil Nadu, India
来源：
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2020年 / 55卷 / 05期
关键词：
SARS-CoV-2; COVID; 19; Baricitinib; Novel Corona Virus;
D O I：
10.1016/j.ijantimicag.2020.105967
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
The Wuhan outbreak of novel Corona virus infection has been the global focus since December 2019. This infection has become a global pandemic. It is highly important to understand the virology of the pathogen and to explore the therapeutic options for management of this pandemic. Drug repurposing strategies are being considered for management of COVID 19. Among the identified drugs, Baricitinib has become a keen interest for researchers because of its ability to inhibit the viral assembly by the prevention of Clarithrin associated endocytosis. We tried to explore the reasons on why Baricitinib is not an ideal option for COVID 19. (C) 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19
    Angelopoulou, Athina
    Alexandris, Nikos
    Konstantinou, Evangelia
    Mesiakaris, Konstantinos
    Zanidis, Charilaos
    Farsalinos, Konstantinos
    Poulas, Konstantinos
    ENVIRONMENTAL RESEARCH, 2020, 188
  • [42] Use of baricitinib in treatment of COVID-19: a systematic review
    Sampath, Ananyan
    Banerjee, Aditya
    Atal, Shubham
    Jhaj, Ratinder
    MEDICINAL RESEARCH REVIEWS, 2023, 43 (05) : 1322 - 1345
  • [43] Baricitinib as the treatment of choice for hospitalised individuals with COVID-19
    Richardson, Peter J.
    Stebbing, Justin
    ECLINICALMEDICINE, 2022, 49
  • [44] Success for a new Generation of Basic Therapeutics The Janus-Kinase -Inhibitor Baricitinib in rheumatoid Arthritis
    Keysser, G.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2017, 76 (05): : 461 - 462
  • [45] Open Label use of the Janus Kinase Inhibitor Baricitinib in a Genetic Interferonopathy, Aicardi Goutieres Syndrome
    Vanderver, A.
    Adang, L.
    Gavazzi, F.
    Ulrick, N.
    Koh, J.
    McDonald, K.
    Peer, K.
    Besnier, C.
    Cross, Z.
    Helman, G.
    Rhee, J.
    Takanohashi, A.
    Armangue, T.
    Goldback-Mansky, R.
    Shults, J.
    ANNALS OF NEUROLOGY, 2019, 86 : S30 - S30
  • [46] Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
    Andre C Kalil
    四川生理科学杂志, 2020, 42 (04) : 451 - 451
  • [47] Current Status of Baricitinib as a Repurposed Therapy for COVID-19
    Saber-Ayad, Maha
    Hammoudeh, Sarah
    Abu-Gharbieh, Eman
    Hamoudi, Rifat
    Tarazi, Hamadeh
    Al-Tel, Taleb H.
    Hamid, Qutayba
    PHARMACEUTICALS, 2021, 14 (07)
  • [48] Refractory cutaneous lichen amyloidosis coexisting with atopic dermatitis responds to the Janus Kinase inhibitor baricitinib
    Xia, Dengmei
    Xiao, Yue
    Li, Mengmeng
    Li, Wei
    DERMATOLOGIC THERAPY, 2022, 35 (09)
  • [49] Rapid improvement of refractory generalized granuloma annulare with the Janus kinase inhibitor baricitinib in two patients
    Kim, Dongchan
    Kang, Hee Young
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2023, 48 (04) : 375 - 376
  • [50] Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
    Kalil, A. C.
    Patterson, T. F.
    Mehta, A. K.
    Tomashek, K. M.
    Wolfe, C. R.
    Ghazaryan, V.
    Marconi, V. C.
    Ruiz-Palacios, G. M.
    Hsieh, L.
    Kline, S.
    Tapson, V.
    Iovine, N. M.
    Jain, M. K.
    Sweeney, D. A.
    El Sahly, H. M.
    Branche, A. R.
    Pineda, J. Regalado
    Lye, D. C.
    Sandkovsky, U.
    Luetkemeyer, A. F.
    Cohen, S. H.
    Finberg, R. W.
    Jackson, P. E. H.
    Taiwo, B.
    Paules, C. I.
    Arguinchona, H.
    Erdmann, N.
    Ahuja, N.
    Frank, M.
    Oh, M.
    Kim, E. -S.
    Tan, S. Y.
    Mularski, R. A.
    Nielsen, H.
    Ponce, P. O.
    Taylor, B. S.
    Larson, L. A.
    Rouphael, N. G.
    Saklawi, Y.
    Cantos, V. D.
    Ko, E. R.
    Engemann, J. J.
    Amin, A. N.
    Watanabe, M.
    Billings, J.
    Elie, M. -C.
    Davey, R. T.
    Burgess, T. H.
    Ferreira, J.
    Green, M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09): : 795 - 807
12345